Journal article
Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer
European urology focus, Vol.4(4), pp.503-505
07/2018
DOI: 10.1016/j.euf.2018.07.005
PMID: 30017900
Abstract
Bacillus Calmette-Guérin (BCG) replaced early intravesical chemotherapeutic agents as the standard of care for non-muscle-invasive bladder cancer (NMIBC) with its US Food and Drug Administration approval in 1990. Multiple studies have proven the superiority of BCG to surgery alone, and to older single-agent intravesical chemotherapy regimens. However, new multiagent intravesical chemotherapy regimens have been developed and tested in recent years. Such regimens offer the possibility of better efficacy and/or tolerability compared to BCG. However, high-quality data comparing such regimens to BCG remain scant. We briefly review the literature regarding combination intravesical chemotherapy for NMIBC.
Details
- Title: Subtitle
- Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer
- Creators
- Ryan L Steinberg - Department of Urology, University of Iowa, Iowa City, IA, USALewis J Thomas - Department of Urology, University of Iowa, Iowa City, IA, USAMichael A O'Donnell - Department of Urology, University of Iowa, Iowa City, IA, USA. Electronic address: michael-odonnell@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- European urology focus, Vol.4(4), pp.503-505
- Publisher
- Netherlands
- DOI
- 10.1016/j.euf.2018.07.005
- PMID
- 30017900
- ISSN
- 2405-4569
- eISSN
- 2405-4569
- Grant note
- P30 CA086862 / NCI NIH HHS
- Language
- English
- Date published
- 07/2018
- Academic Unit
- Urology
- Record Identifier
- 9984051516202771
Metrics
17 Record Views